Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab

Clinical and Experimental Allergy

Volumn 43, Issue 6, 2013, Pages 659-664

  Matucci, A ^a   Pratesi, S ^b   Petroni, G ^b   Nencini, F ^b   Virgili, G ^a   Milla, M ^a   Maggi, E ^b   Vultaggio, A ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adverse reactions; Hypersensitivity; Infliximab; Skin testing

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; INFLIXIMAB;

ADULT; ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; FEMALE; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; PRICK TEST; PRIORITY JOURNAL; SKIN TEST;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SKIN TESTS;

EID: 84878358699     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12098     Document Type: Article

References (21)

1. Borchers AT, Leibushor N, Cheema GS, Naguwa SM, Gershwin ME. Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun 2011; 37:273-88.
2. Pascual-Salcedo D, Plasencia C, Ramiro S et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011; 50:1445-52.
3. Chung CH, Mirakhur B, Chan E et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-a-1, 3-galactose. N Engl J Med 2008; 358:1109-17.
4. Vultaggio A, Matucci A, Nencini F et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65:657-61.
5. Vultaggio A, Matucci A, Nencini F et al. Drug-Specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. Int Arch Allergy Immunol 2012; 159:321-6.
6. Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010; 32:1597-609.
7. Munoz-Cano R, Carnes J, Sanchez-Lopez J et al. Biological agents: new drugs, old problems. J Allergy Clin Immunol 2010; 126:394-5.
8. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009; 124:1259-66.
9. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114:371-6.
10. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008; 48:1267-81.
11. Erwin EA, Custis NJ, Satinover SM et al. Quantitative measurement of IgE antibodies to purified allergens using streptavidin linked to a high-capacity solid phase. J Allergy Clin Immunol 2005; 115:1029-35.
12. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011; 7:55-63.
13. Matucci A, Parronchi P, Vultaggio A et al. Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients. Allergy 2004; 59:1133-4.
14. Scherer K, Harr T, Bach S, Bircher AJ. The role of iodine in hypersensitivity reactions to radio contrast media. Clin Exp Allergy 2010; 40:468-75.
15. Romano A, Torres MJ, Castells M, Sanz ML, Blanca M. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011; 127:S67-73.
16. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007; 46:1828-34.
17. Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 2007; 120:506-15.
18. Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol 2011; 11:262-8.
19. van der Laken CJ, Voskuyl AE, Roos JC et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007; 66:253-6.
20. Fernández TD, Torres MJ, Blanca-López N et al. Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins. Allergy 2009; 64:242-8.
21. Vultaggio A, Matucci A, Parronchi P et al. Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. Int J Immunopathol Pharmacol 2008; 21:367-74.